down arrow

NexImmune, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US65344D2080
USD
0.00
0 (0.00%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

0.001.01
Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

How big is NexImmune, Inc.?

22-Jun-2025

As of Jun 18, NexImmune, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -20.62 million over the latest four quarters. As of Dec'23, the company reported shareholder's funds of 3.51 million and total assets of 8.59 million.

Market Cap: As of Jun 18, NexImmune, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, NexImmune reported net sales of 0.00 million and a net profit of -20.62 million.<BR><BR>Balance Sheet Snapshot: As of Dec'23, the company had shareholder's funds amounting to 3.51 million and total assets of 8.59 million.

Read More

Is NexImmune, Inc. technically bullish or bearish?

20-Sep-2025

As of February 28, 2025, NexImmune, Inc. shows a mildly bearish trend with mixed indicators, including mildly bullish MACD readings and a significant year-to-date decline of 99.83%, starkly underperforming the S&P 500's 12.22% gain.

As of 28 February 2025, the technical trend for NexImmune, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. The monthly RSI is bullish, suggesting underlying strength, but the daily moving averages are mildly bearish, which could be a concern in the short term. Overall, the Bollinger Bands are sideways, indicating a lack of volatility in both weekly and monthly time frames. <BR><BR>In terms of performance, the stock has seen a significant decline year-to-date, down 99.83%, compared to a 12.22% gain in the S&P 500. Over the past year, the stock is down 99.98%, while the S&P 500 has returned 17.14%. This stark contrast highlights the stock's severe underperformance relative to the benchmark.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-2.44

stock-summary
Return on Equity

-1,939.19%

stock-summary
Price to Book

0.00

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2024)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0%
0%
0.0%
6 Months
0%
0%
0.0%
1 Year
-99.97%
0%
-99.97%
2 Years
-100.0%
0%
-100.0%
3 Years
-99.98%
0%
-99.98%
4 Years
-100.0%
0%
-100.0%
5 Years
0%
0%
0.0%

NexImmune, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is NexImmune, Inc. technically bullish or bearish?

As of 28 February 2025, the technical trend for NexImmune, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish, indicating some positive momentum. The monthly RSI is bullish, suggesting underlying strength, but the daily moving averages are mildly bearish, which could be a concern in the short term. Overall, the Bollinger Bands are sideways, indicating a lack of volatility in both weekly and monthly time frames. In terms of performance, the stock has seen a significant decline year-to-date, down 99.83%, compared to a 12.22% gain in the S&P 500. Over the past year, the stock is down 99.98%, while the S&P 500 has returned 17.14%. This stark contrast highlights the stock's severe underperformance relative to the benchmark....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
15.14%
EBIT to Interest (avg)
-41.09
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.44
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
31.68%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
0.00
EV to EBIT
0.14
EV to EBITDA
0.15
EV to Capital Employed
1.60
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1120.38%
ROE (Latest)
-1939.19%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bullish
Bearish
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 0.00% vs 0.00% in Jun 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2024 is 69.74% vs 52.20% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.70",
          "val2": "-7.20",
          "chgp": "62.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "1.20",
          "val2": "-0.10",
          "chgp": "1,300.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.30",
          "val2": "-7.60",
          "chgp": "69.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 48.32% vs -22.79% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-28.20",
          "val2": "-61.60",
          "chgp": "54.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-32.30",
          "val2": "-62.50",
          "chgp": "48.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'24 - YoYstock-summary
Jun'24
Jun'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.70
-7.20
62.50%
Interest
0.00
0.00
Exceptional Items
1.20
-0.10
1,300.00%
Consolidate Net Profit
-2.30
-7.60
69.74%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2024 is 0.00% vs 0.00% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2024 is 69.74% vs 52.20% in Jun 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-28.20
-61.60
54.22%
Interest
0.00
0.00
Exceptional Items
-3.10
0.00
Consolidate Net Profit
-32.30
-62.50
48.32%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 48.32% vs -22.79% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About NexImmune, Inc. stock-summary
stock-summary
NexImmune, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."